Guggenheim raised the firm’s price target on Tarsus Pharmaceuticals (TARS) to $90 from $87 and keeps a Buy rating on the shares after the company delivered “strong” 2025 results. With 2026 sales guidance of $670M-$700M and only a small fraction of the up to 25M patient DB market penetrated, Tarsus is “well-positioned for sustained growth,” the analyst tells investors.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TARS:
- Tarsus Pharmaceuticals rises 11.6%
- Tarsus Pharmaceuticals price target raised to $90 from $88 at BofA
- Sustained Growth Outlook for Tarsus Driven by XDEMVY’s Rapid Ramp and Expanding Lotilaner Pipeline
- Tarsus: Strong Xdemvy Launch, Upgraded Long‑Term Outlook, and Underappreciated Earnings Power Support Buy Rating
- Tarsus: Raising Peak Xdemvy Outlook to $2B+ on Strong Q4 Momentum and Pipeline Upside